Lamotrigine

The Defense Logistics Agency Troop Support Medical (DLA Medical Supply Chain) is soliciting a contract for Lamotrigine, a pharmaceutical product classified under NAICS category 325412 for Pharmaceutical Preparation Manufacturing. This solicitation, identified as SPE2D2-25-R-0002, seeks to procure pharmaceutical supplies with a specific focus on Lamotrigine, a medication commonly used to treat epilepsy and bipolar disorder. The contract opportunity was posted on November 25, 2024, with proposals due by January 9, 2025, indicating a comprehensive timeline for potential bidders to prepare and submit their responses. Interested contractors must carefully review the detailed solicitation document to understand the specific technical requirements, quality standards, and compliance expectations for the pharmaceutical product. The evaluation criteria will likely include factors such as manufacturing capabilities, product quality, pricing, delivery timelines, and the vendor's ability to meet stringent medical supply chain standards.

This solicitation does not indicate a specific set-aside designation, suggesting the competition is open to a broad range of pharmaceutical manufacturers and suppliers. While the exact award value is not specified in the available information, the contract appears to be a significant procurement within the Defense Logistics Agency's medical supply chain. The procurement is categorized under Product Service Code 6505 for Drugs and Biologicals, which provides additional context about the type of medical product being sought. Potential bidders should anticipate a comprehensive review process that will assess not just pricing, but also manufacturing capabilities, quality control measures, and the ability to consistently supply the required pharmaceutical product. The contract likely involves substantial quantities of Lamotrigine to support military medical facilities and personnel, though precise volume requirements would be detailed in the full solicitation document.